Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Diabetes mellitus in chronic kidney disease: Biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Hemoglobin A1c-levels and subsequent risk of depression in individuals with and without diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Psychosocial health in people with diabetes during the first three months of the COVID-19 pandemic in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Silent atrial fibrillation detected by home-monitoring: Cardiovascular disease and stroke prevention in patients with diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Prediction of carotid intima-media thickness and its relation to cardiovascular events in persons with type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Sidar Copur
  • Emine M Onal
  • Baris Afsar
  • Alberto Ortiz
  • Daniel H van Raalte
  • David Z Cherney
  • Peter Rossing
  • Mehmet Kanbay
Vis graf over relationer

Diabetes mellitus (DM) is the leading cause of chronic kidney disease (CKD). Optimal glycemic control contributes to improved outcomes in patients with DM, particularly for microvascular damage, but blood glucose levels are too variable to provide an accurate assessment and instead markers averaging long-term glycemic load are used. The most established glycemic biomarker of long-term glycemic control is HbA1c. Nevertheless, HbA1c has pitfalls that limit its accuracy to estimate glycemic control, including the presence of altered red blood cell survival, hemoglobin glycation and suboptimal performance of HbA1c assays. Alternative methods to evaluate glycemic control in patients with DM include glycated albumin, fructosamine, 1-5 anhydroglucitol, continuous glucose measurement, self-monitoring of blood glucose and random blood glucose concentration measurements. Accordingly, our aim was to review the advantages and pitfalls of these methods in the context of CKD.

OriginalsprogEngelsk
Artikelnummer107707
TidsskriftJournal of Diabetes and its Complications
Vol/bind34
Udgave nummer11
Sider (fra-til)107707
ISSN1056-8727
DOI
StatusUdgivet - nov. 2020

Bibliografisk note

Copyright © 2020 Elsevier Inc. All rights reserved.

ID: 61379131